Cite
MLA Citation
Rima K. Acosta et al.. “Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.” Journal of acquired immune deficiency syndromes, vol. 85, 2020, p. . http://access.bl.uk/ark:/81055/vdc_100152022835.0x000016